In this study, we found that the ablation of Trappc9 resulted in disruption of systemic glucose homeostasis, which was associated with hyperinsulinemia, hyperleptinemia, hyperprolactinemia, dyslipidemia, adipocyte hypertrophy, and glucose metabolism reprogramming and lipid accumulation in the liver. Here, TRAPPC9 is linked to metabolic syndrome.